MacroGenics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are against FY2022. This is an annual filing, and the supplied text does not provide standalone Q4 results. MacroGenics is an antibody-based biopharmaceutical company focused primarily on oncology, with clinical and preclinical programs and partnered products.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $58.7 million | $151.9 million |
| Operating loss | $168.2 million | $121.4 million |
| Net loss | $9.1 million | $119.8 million |
| R&D expense | $166.6 million | $207.0 million |
| SG&A expense | $52.2 million | $58.9 million |
| Net cash used in operating activities | $78.2 million | $87.0 million |
- Revenue declined 61%, mainly because FY2022 included a $60 million TZIELD approval milestone and higher revenue under Provention, Zai Lab, Incyte and I-Mab agreements. FY2023 revenue included $29.0 million from collaborative and other agreements, $17.9 million of MARGENZA sales, $9.8 million of contract manufacturing, $0.4 million of royalties and $1.6 million of government agreements.
- Net loss improved despite the larger operating loss, primarily because of a $150.9 million gain related to the TZIELD royalty monetization and $9.7 million of interest and other income. The gain is unusual and non-recurring; it should not be viewed as evidence of operating profitability.
- R&D fell 20%, reflecting lower spending on vobra duo manufacturing, margetuximab, flotetuzumab, enoblituzumab and tebotelimab; increased spending on lorigerlimab, MGC026 and newly advanced MGC028 partly offset the reductions.
- At year-end, cash and cash equivalents were $101.0 million and marketable securities were $128.8 million, totaling $229.8 million. Current assets were $251.3 million versus current liabilities of $56.1 million. The company reported total liabilities of $145.8 million, including $80.9 million of deferred revenue and $34.0 million of lease liabilities. The royalty-related liability was reduced to zero following amendments to the royalty transaction; no other borrowing balance is identified in the supplied financial statements.
- Operating cash use was $78.2 million. Investing activities used $80.1 million, primarily for purchases of marketable securities, while financing activities provided $150.4 million, principally from the royalty transaction. Cash and cash equivalents decreased $7.9 million during the year.
- Management expects year-end cash, cash equivalents and marketable securities, together with anticipated and potential collaboration payments, product revenue, manufacturing revenue and royalties, to fund operations into 2026. The estimate excludes potential costs of late-stage vobra duo development. Management also states current resources are sufficient for at least 12 months from the filing date.
Material developments and outlook
- Vobra duo: TAMARACK Phase 2 enrollment in mCRPC completed in Q4 2023 with 177 patients, exceeding the planned enrollment. A clinical update was expected in Q2 2024, with possible further updates later in 2024; dosing in additional tumor cohorts was expected to begin in mid-2024.
- Lorigerlimab: The randomized Phase 2 LORIKEET trial in mCRPC began in the second half of 2023. The company planned an update in the second half of 2024. Earlier exploratory results cited in the filing include confirmed partial responses in 9 of 35 evaluable mCRPC patients; these preliminary data do not establish later-stage efficacy.
- MGC026 and MGC028: MGC026 entered Phase 1 dose escalation. The company anticipated presenting MGC028 preclinical data in April 2024 and submitting an IND by year-end 2024; these are forward-looking plans, not completed milestones.
- Partner and product changes: Zai Lab gave notice in November 2023 to terminate its agreement covering MARGENZA and tebotelimab, effective May 2024. MARGENZA had received Chinese approval in August 2023, but the filing says the partner had not commercialized it. MacroGenics has no ongoing tebotelimab studies. Development of IMGC936 was discontinued after it did not meet pre-established safety and efficacy benchmarks.
- Partnered economics: Incyte’s ZYNYZ received FDA approval in March 2023. MacroGenics may receive further Incyte milestones and tiered royalties of 15%–24% on global net sales. Gilead paid a $15.7 million research-program nomination fee in 2023 and may exercise options under the collaboration; the stated potential payments of up to $1.7 billion depend on multiple options and development and commercial successes and are not assured.
- Risks and contingencies: The company has an accumulated deficit of approximately $1.1 billion and expects continued losses. Funding availability, clinical efficacy and safety, regulatory review, manufacturing capacity and supply, competition, reimbursement, intellectual-property disputes, and reliance on partners could materially affect results. The enoblituzumab combination study in head and neck cancer was discontinued in 2022 following an internal safety review. MARGENZA carries boxed warnings for left ventricular dysfunction and embryo-fetal toxicity.
- Other notable items: The royalty transaction generated a $100.9 million accounting gain following its modification and a further $50.0 million gain upon achievement of a TZIELD study milestone. The company retains certain TZIELD milestone and royalty interests. It reported no off-balance-sheet arrangements. The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also assessed internal control over financial reporting as effective.
Most important facts for investors to verify
- Whether the expected TAMARACK data and other 2024 clinical milestones were delivered, and what the complete, updated efficacy and safety results show.
- Whether LORIKEET progresses as planned and whether its results support further development of lorigerlimab.
- Actual cash burn, collaboration receipts and MARGENZA sales relative to management’s stated runway into 2026, especially if vobra duo enters late-stage development.
- The commercial and financial effects of Zai Lab’s termination, including the status of MARGENZA in China and any transition of relevant rights.
- Whether Incyte’s ZYNYZ launches and sales generate royalties or milestones for MacroGenics, and whether Gilead exercises its options; headline potential payments are contingent.
- Whether clinical, manufacturing, partner, safety, regulatory or financing developments require changes to program priorities or liquidity expectations.